DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Atelvia (Risedronate Sodium Hemi-Pentahydrate / Risedronate Sodium Monohydrate) - Published Studies

 
 



Atelvia Related Published Studies

Well-designed clinical trials possibly related to Atelvia (Risedronic Acid / Risedronic Acid)

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis. [2013]

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. [2013]

Lipid profiles within the SABRE trial of anastrozole with and without risedronate. [2012]

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. [2012]

Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. [2012]

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. [2012]

Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. [2011]

Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. [2011]

Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. [2010]

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. [2010]

Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. [2010]

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. [2009]

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. [2009]

Risedronate on two consecutive days per month. [2009]

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. [2009]

LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. [2009]

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. [2009]

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. [2009]

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. [2008]

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. [2008]

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. [2008]

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. [2008]

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. [2008]

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. [2008]

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. [2007]

A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. [2007]

[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis]. [Article in Japanese] [2006]

Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. [2006]

Between-meal risedronate does not alter bone turnover in nursing home residents. [2006]

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006]

Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. [2005]

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. [2005]

Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. [2005]

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. [2005]

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. [2005]

Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. [2005]

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. [2005]

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. [2005]

The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. [2005]

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. [2005]

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. [2004]

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. [2004]

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. [2004]

The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. [2004]

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. [2004]

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. [2004]

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. [2004]

Risedronate once a week. [2003]

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. [2003]

Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. [2003]

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). [2003]

Risedronate prevents new vertebral fractures in postmenopausal women at high risk. [2003]

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. [2002]

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. [2002]

Tolerability of risedronate in postmenopausal women intolerant of alendronate. [2001]

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. [2001]

Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma. [2001]

Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. [2001]

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. [2001]

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. [2000]

Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. [2000]

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. [2000]

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. [2000]

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. [2000]

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. [2000]

Oral bisphosphonates: A review of clinical use in patients with bone metastases. [2000]

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [1999]

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. [1999]

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. [1999]

Risedronate. [1998]

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. [1998]

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. [1997]

Other research related to Atelvia (Risedronic Acid / Risedronic Acid)

Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. [2009]

Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international. [2006]

Other possibly related research studies

Effect of risedronate on bone in renal transplant recipients. [2012]

Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? [2012]

Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. [2012]

Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. [2011]

Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis. [2011]

Effect of stopping risedronate after long-term treatment on bone turnover. [2011]

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. [2011]

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial. [2011]

The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. [2011]

The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. [2011]

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. [2011]

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. [2011]

Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. [2010]

Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. [2010]

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. [2010]

Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. [2010]

Review of osteoporosis pharmacotherapy for geriatric patients. [2009]

Effect of osteoporosis treatment on mortality: a meta-analysis. [2010]

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. [2009]

Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease. [2009]

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial. [2010]

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. [2009]

The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. [2010]

Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. [2009]

Risedronate reduces intracortical porosity in women with osteoporosis. [2010]

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. [2010]

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. [2009]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017